PMID- 38506033
OWN - NLM
STAT- MEDLINE
DCOM- 20240321
LR  - 20240321
IS  - 0028-2685 (Print)
IS  - 0028-2685 (Linking)
VI  - 71
IP  - 1
DP  - 2024 Feb
TI  - Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small 
      cell lung cancer.
PG  - 88-97
LID - 230517N262 [pii]
LID - 10.4149/neo_2024_230517N262 [doi]
AB  - Neoadjuvant chemoimmunotherapy plays a crucial role in resectable non-small cell 
      lung cancer (NSCLC). Neoadjuvant chemotherapy before sleeve lobectomy was safe 
      and feasible, but the impact of neoadjuvant chemoimmunotherapy before sleeve 
      lobectomy was unclear. In our retrospective study, patients diagnosed as stage 
      IIB to IIIB resectable NSCLC between December 1, 2018 and December 1, 2020 in the 
      Department of Thoracic Surgery, Zhejiang Cancer Hospital were collected. We 
      analyzed the efficacy and safety of neoadjuvant chemoimmunotherapy for resectable 
      NSCLC patients and analyzed the impact of different types of surgery on 
      postoperative complications, surgical difficulty, and long-term survival. In 
      total, 56 patients were included in this retrospective study. With a median 
      follow-up of 35 months, 1-year EFS, 2-year EFS, and 3-year EFS were 87.5%, 80.4%, 
      and 76.7%, respectively. 1-year OS, 2-year OS, and 3-year OS were 96.4%, 91.1%, 
      and 85.6%. respectively. Both median EFS and OS were not reached. The percentage 
      of patients with pCR was 51.8%. 48 (85.7%) patients had nodal downstaging and 
      primary tumor downstaging. In 40 (61.4%) patients occurred neoadjuvant 
      chemoimmunotherapy-related adverse events (AEs), most of them of Grade 1 and 2. 
      Postoperative complications occurred in 19 (33.9%) patients. Subgroup analysis 
      showed that sleeve lobectomy was related to better survival and had no impact on 
      operation duration, hospital stay, intraoperative blood loss, and postoperative 
      complications. Neoadjuvant chemoimmunotherapy led to a high pCR rate, favorable 
      3-year survival rate, and acceptable AEs. Sleeve lobectomy was safe and related 
      to better survival.
FAU - Ji, Wenhao
AU  - Ji W
AD  - Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute 
      of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
AD  - Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
FAU - Jiang, Youhua
AU  - Jiang Y
AD  - Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of 
      Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
FAU - Li, Yuetong
AU  - Li Y
AD  - Graduate School, Wenzhou Medical University, Wenzhou, Zhejiang, China.
FAU - Mao, Weimin
AU  - Mao W
AD  - Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of 
      Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
FAU - Teng, Lisong
AU  - Teng L
AD  - Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute 
      of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
PL  - Slovakia
TA  - Neoplasma
JT  - Neoplasma
JID - 0377266
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Lung Neoplasms/drug therapy
MH  - Neoadjuvant Therapy
MH  - Follow-Up Studies
MH  - Retrospective Studies
MH  - Neoplasm Staging
MH  - Postoperative Complications
EDAT- 2024/03/20 06:45
MHDA- 2024/03/21 12:46
CRDT- 2024/03/20 04:53
PHST- 2023/05/17 00:00 [received]
PHST- 2024/02/22 00:00 [accepted]
PHST- 2024/03/21 12:46 [medline]
PHST- 2024/03/20 06:45 [pubmed]
PHST- 2024/03/20 04:53 [entrez]
AID - 230517N262 [pii]
AID - 10.4149/neo_2024_230517N262 [doi]
PST - ppublish
SO  - Neoplasma. 2024 Feb;71(1):88-97. doi: 10.4149/neo_2024_230517N262.